GHRP-2
GHRP-2 (pralmorelin) is a synthetic hexapeptide that potently stimulates growth hormone release by mimicking ghrelin at the GHS-R1a receptor on pituitary somatotrophs. It is the most potent GHRP in terms of peak GH release — producing larger GH pulses than ipamorelin, GHRP-6, or hexarelin — but with a less clean side effect profile. Unlike ipamorelin, GHRP-2 significantly increases cortisol (~20-40% transient elevation) and prolactin (~50-100% transient elevation), which limits its use in protocols where hormonal cleanliness matters. It also stimulates appetite via ghrelin pathway activation, though less than GHRP-6. GHRP-2 is approved in Japan as a diagnostic agent for GH deficiency (pralmorelin/GHRP Kaken). The synergy with GHRH analogs (CJC-1295, mod-GRF 1-29) is well-documented: GHRP-2 + GHRH produces 5-10x the GH release of either alone. Preferred by users who want maximum GH output and tolerate the cortisol/prolactin trade-off.
Current literature links
Evidence
No score yet
Safety
Unknown safety profile
Clinical Status
Phase II (diagnostic use approved in Japan as pralmorelin)
Last Sync
Not synced yet
Last Reviewed
Not reviewed yet
Dosing
Set height & weight in Settings to see your dose.
Pharmacology
Evidence Score
Plain-English Snapshot
GHRP-2 is currently categorized as a peptide compound.
Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.
Safety scoring is incomplete. Start conservatively and monitor carefully.
Core mechanism
Potent ghrelin mimetic at GHS-R1a; amplifies GH pulse via calcium-dependent exocytosis; also activates ACTH/cortisol and prolactin pathways (less selective than ipamorelin)
Practical Context
Strongest current signals
No indexed study summaries yet.